Inhibitor Therapeutics, Inc. INTI
Set alert
At close · Oct 30
- YTD
- +115.56%
- 1 year
- +94.00%
- Open
- 0.0611
- Prev close
- 0.065
- Mkt cap
- 16.95M
- Vol
- 90.00K
- Avg vol
- 9.15K
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.0611
- High
- 0.0611
News
1 month ago globenewswire.com
Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly…
7 months ago globenewswire.com
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical…
1 year ago globenewswire.com
Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
2 years ago globenewswire.com
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight
The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria…
2 years ago globenewswire.com
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the…
2 years ago zacks.com
3 Intriguing Stocks to Watch as Earnings Approach
As beneficiaries of strong business industries, Intuit (INTU), Workday (WDAY), and Booz Allen Hamilton's (BAH) stock all sport a Zacks Rank #2 (Buy) ahead of their quarterly reports this week.
2 years ago prnewswire.com
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application ("NDA") to FDA TAMPA, Fla. , Dec. 19, 2023…